Man Group
MLNT

Man Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Man Group’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30,708
Closed -$1.14M – 2293
2018
Q1 		$1.14M Buy
+30,708
New +$2.02M 0.01% 1477

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group's MLNT Position: Q2 2018 in Review

Man Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2018, closing a stake of 30,708 shares — an estimated $1.14M sold.

Man Group first reported a position in MLNT in Q1 2018 and held it in 1 quarter. The position peaked at $1.14M in Q1 2018. 87 funds tracked by Wall St. Rank hold MLNT as of Q2 2018.

  • Man Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Man Group sold 30,708 Melinta Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $1.14M.
  • Man Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Man Group's Melinta Therapeutics, Inc. Common Stock position peaked at $1.14M in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Man Group's 13F filing for Q2 2018, filed 14 Aug 2018.